BNOX (Bionomics) Land And Improvements : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bionomics Land And Improvements?

Bionomics's land and improvements for the quarter that ended in Sep. 2024 was $0.00 Mil.

Bionomics Land And Improvements Historical Data

The historical data trend for Bionomics's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionomics Land And Improvements Chart

Bionomics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Land And Improvements

Get a 7-Day Free Trial

Bionomics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Bionomics Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Bionomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bionomics Ltd (NAS:BNOX) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

B1N0:Germany B1N0:Germany

Address

200 Greenhill Road, Eastwood, SA, AUS, 5063

Website

https://www.bionomics.com.au

Bionomics Ltd is a clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.